•                The new Mini-site
                             is online!
  • Research
  • Excellence
    of Production
  • Promoting

Ongoing Malaria Project Activities

The collaboration between sigma-tau and the Medicine for Malaria Venture (MMV), which came about to develop and distribute the DHA/PQP combination in film-coated tablets on a large scale, has also included the development of a water-soluble formula to be used in treating children with uncomplicated P. falciparum malaria. Clinical trials of this new formula on young children between the ages of 6 and 12 months are currently being conducted in 5 African countries (Mozambique, Burkina Faso, Gambia, Tanzania and the Democratic Republic of Congo). The study will conclude in 2014 after having treated 200 children with the new paediatric formula.

A clinical study to confirm the efficacy of the DHA/PQP formula in treating uncomplicated Plasmodium vivax malaria has recently been added. This type of malaria is especially widespread in Asia, Oceania and South America.

Within this context, sigma-tau has begun a collaboration with the European Network of Tropical Medicine (TROPNET) to continue the experimentation at 15 TROPNET-affiliated centres in 9 European countries (Italy, France, Switzerland, France, Spain, The Netherlands, Belgium and Great Britain). The study is currently under examination by ethics committees and regulatory authorities. The experimentation phase will have a duration of two years starting in early 2014 and will involve 100 adult patients suffering from “imported malaria”, that is, malaria in travellers who are infected in endemic countries but whose symptoms appear (and are confirmed) only after their return to Europe.

>> Read more

  UPDATE TO 28/01/2014
2015© sigma-tau s.p.a. | VAT no. 00885531004